Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD

International Journal of Geriatric Psychiatry

Volumn 27, Issue 2, 2012, Pages 127-134

  Rami, Lorena ^a   Solé Padullés, Cristina ^a   Fortea, Juan ^a   Bosch, Beatriz ^a   Lladõ, Albert ^a,b   Antonell, Anna ^a   Olives, Jaume ^a   Castellví, Magda ^a   Bartres Faz, David ^c   Sánchez Valle, Raquel ^a,b   Molinuevo, Jose Luis ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alzheimer's disease; amyloid; cerebrospinal fluid; cognition; diagnosis; magnetic resonance imaging; mild cognitive impairment; neuroimage; neuropsychological tests

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN ATROPHY; CEREBELLUM; CEREBROSPINAL FLUID; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; EPISODIC MEMORY; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MEMORY DISORDER; MIDDLE FRONTAL GYRUS; NEUROIMAGING; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAHIPPOCAMPAL GYRUS; PRECUNEUS; RECALL; SUPERIOR TEMPORAL GYRUS; UNCUS; VOXEL BASED MORPHOMETRY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMNESIA; ATROPHY; BIOLOGICAL MARKERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; TAU PROTEINS;

EID: 79958115821     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2696     Document Type: Article

References (31)

1. Andreasen N, Blennow K,. 2005. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 107: 165-173.
2. Blennow K, Hampel H,. 2003. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605-613. (Pubitemid 37162569)
3. Bouwman FH, Verwey NA, Klein M, et al,. 2010. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 30: 1-7.
4. Braak H, Braak E,. 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
5. Daly E, Zaitchik D, Copeland M, et al,. 2000. Predicting conversation to Alzheimer disease using standardized clinical information. Arch Neurol 57: 675-680. (Pubitemid 30252802)
6. De Lepeleire J, Wind AW, Iliffe S, et al,. Interdem Group. 2008. The primary care diagnosis of dementia in Europe: an analysis using multidisciplinary, multinational expert groups. Aging Ment Health 12: 568-576.
7. Dubois B, Feldman HH, Jacova C, et al,. 2007. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet 6: 734-746. (Pubitemid 47058377)
8. Fagan AM, Mintun MA, Mach RH, et al,. 2006. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A-42 in humans. Ann Neurol 59: 512-519. (Pubitemid 43358072)
9. Fagan AM, Roe CM, Xiong C, et al,. 2007. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-349. (Pubitemid 46425688)
10. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA,. 1987. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149: 351-356. (Pubitemid 17104996)
11. Fjell AM, Amlien IK, Westlye LT, et al,. 2010. CSF biomarker pathology correlates with a medial temporo-parietal network affected by very mild to moderate Alzheimer's disease but not a fronto-striatal network affected by healthy aging. Neuroimage 49: 1820-1830.
12. Fjell AM, Walhovd KB, Fennema-Notestine C, et al,. Alzheimer's Disease Neuroimaging Initiative. 2010. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci 30: 2088-2101.
13. Grober E, Buschke H,. 1987. Genuine memory deficits in dementia. Dev Neuropsychol 3: 13-36.
14. Hansson O, Zetterberg H, Buchhave P, et al,. 2006. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234. (Pubitemid 43238346)
15. Hildebrandt H, Haldenwanger A, Eling P,. 2009. False recognition correlates with amyloid-1-42 but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment. J Alzheimers Dis 16: 157-165.
16. Iliffe S, Manthorpe J, Eden A,. 2003. Sooner or later? Issues in the early diagnosis of dementia in general practice: a qualitative study. Fam Pract 20: 376-381. (Pubitemid 36939663)
17. Jack CR Jr, Knopman DS, Jagust WJ, et al,. 2010. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128.
18. Lin YT, Cheng JT, Yao YC, et al,. 2009. Increased total TAU but not amyloid-beta (42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. J Alzheimers Dis 18: 907-918.
19. Moonis M, Swearer JM, Dayaw MP, et al,. 2005. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 65: 323-325. (Pubitemid 41022387)
20. Morris JC,. 1993. The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412-2414. (Pubitemid 23346995)
21. Petersen RC, Smith GE, Waring SC, et al,. 1999. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308. (Pubitemid 29120227)
22. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S,. 1982. Measurement of functional activities in older adults in the community. J Gerontol 37: 323-329. (Pubitemid 12117513)
23. Rami L, Gõmez-Anson B, Sanchez-Valle R, et al,. 2007. Longitudinal study of amnesic patients at high risk for Alzheimer's disease: clinical, neuropsychological and magnetic resonance spectroscopy features. Dement Geriatr Cogn Disord 24: 402-410. (Pubitemid 350036698)
24. Rami L, Gõmez-Anson B, Monte GC, et al,. 2009. Voxel based morphometry features and follow-up of amnestic patients at high risk for Alzheimer's disease conversion. Int J Geriatr Psychiatry 24: 875-884.
25. Ringman JM, Younkin SG, Pratico D, et al,. 2008. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71: 85-92.
26. Schoonenboom NS, Pijnenburg YA, Mulder C, et al,. 2004. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62: 1580-1584. (Pubitemid 38608199)
27. Schoonenboom SN, Visser PJ, Mulder C, et al,. 2005. Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 11: 8-13. (Pubitemid 40372855)
28. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al,. 2009. Alzheimer's disease neuroimaging initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403-413.
29. Snider BJ, Fagan AM, Roe C, et al,. 2009. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66: 638-645.
30. Sunderland T, Linker G, Mirza N, et al,. 2003. Decreased amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289: 2094-2103. (Pubitemid 37430211)
31. Winblad B, Wimo A, Engedal K, et al,. 2006. 3-Year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 21: 353-363. (Pubitemid 43735680)